Total Payments
$883.67
2024 Payments
$234.72
Companies
10
Transactions
39
Medicare Patients
607
Medicare Billing
$128,925
Payment Breakdown by Category
Food & Beverage$853.68 (96.6%)
Education$29.99 (3.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $853.68 | 38 | 96.6% |
| Education | $29.99 | 1 | 3.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $272.33 | 7 | $0 (2023) |
| Indivior Inc. | $136.75 | 9 | $0 (2024) |
| ABBVIE INC. | $121.76 | 1 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $103.27 | 7 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $78.45 | 5 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $55.54 | 4 | $0 (2023) |
| Neurocrine Biosciences, Inc. | $48.33 | 3 | $0 (2021) |
| Allergan Inc. | $29.99 | 1 | $0 (2018) |
| Lundbeck LLC | $19.00 | 1 | $0 (2024) |
| BioXcel Therapeutics, Inc. | $18.25 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $234.72 | 8 | ABBVIE INC. ($121.76) |
| 2023 | $126.24 | 8 | Indivior Inc. ($29.78) |
| 2022 | $75.52 | 5 | Otsuka America Pharmaceutical, Inc. ($30.17) |
| 2021 | $190.99 | 8 | Alkermes, Inc. ($122.09) |
| 2019 | $30.49 | 2 | Janssen Pharmaceuticals, Inc ($16.43) |
| 2018 | $225.71 | 8 | Alkermes, Inc. ($104.71) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/07/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $19.00 | General |
| Category: PSYCHIATRY | ||||||
| 07/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $121.76 | General |
| Category: NEUROSCIENCE | ||||||
| 05/08/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: BH | ||||||
| 04/30/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: BH | ||||||
| 03/29/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: BH | ||||||
| 02/15/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: BH | ||||||
| 01/24/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: BH | ||||||
| 01/16/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: Neuroscience | ||||||
| 10/11/2023 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Neurology | ||||||
| 10/03/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: BH | ||||||
| 09/20/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $13.38 | General |
| Category: PSYCHIATRY | ||||||
| 07/31/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: CNS | ||||||
| 07/13/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: PSYCHIATRY | ||||||
| 05/30/2023 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Neuroscience | ||||||
| 03/07/2023 | BioXcel Therapeutics, Inc. | IGALMI (Drug) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2023 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: BH | ||||||
| 07/13/2022 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: BH | ||||||
| 06/01/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: CNS | ||||||
| 04/06/2022 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: PSYCHIATRY | ||||||
| 03/30/2022 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: Neuroscience | ||||||
| 03/23/2022 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2021 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROLOGY | ||||||
| 09/28/2021 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $11.56 | General |
| Category: Central Nervous System | ||||||
| 08/03/2021 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: PSYCHIATRY | ||||||
| 07/13/2021 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 152 | 614 | $191,111 | $37,517 |
| 2022 | 5 | 142 | 546 | $165,926 | $32,618 |
| 2021 | 4 | 152 | 511 | $167,184 | $32,996 |
| 2020 | 4 | 161 | 382 | $92,128 | $25,794 |
Total Patients
607
Total Services
2,053
Medicare Billing
$128,925
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 45 | 271 | $82,435 | $18,213 | 22.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 51 | 280 | $53,686 | $11,898 | 22.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 33 | 37 | $42,306 | $4,898 | 11.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 23 | 26 | $12,685 | $2,507 | 19.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 307 | $92,873 | $19,001 | 20.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 32 | 167 | $27,365 | $5,620 | 20.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 33 | 36 | $32,336 | $5,260 | 16.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 12 | 16 | $7,211 | $1,483 | 20.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 19 | 20 | $6,140 | $1,254 | 20.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 63 | 384 | $121,152 | $23,456 | 19.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 29 | 30 | $20,432 | $4,236 | 20.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 45 | 50 | $16,200 | $3,105 | 19.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 47 | $9,400 | $2,200 | 23.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 61 | 251 | $49,698 | $15,845 | 31.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 53 | 54 | $27,000 | $6,316 | 23.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 30 | 30 | $6,030 | $1,937 | 32.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 47 | $9,400 | $1,696 | 18.0% |
About Dr. Alexandr Dron, M.D
Dr. Alexandr Dron, M.D is a Addiction Psychiatry healthcare provider based in Northfield, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2013. The National Provider Identifier (NPI) number assigned to this provider is 1295170439.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexandr Dron, M.D has received a total of $883.67 in payments from pharmaceutical and medical device companies, with $234.72 received in 2024. These payments were reported across 39 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($853.68).
As a Medicare-enrolled provider, Dron has provided services to 607 Medicare beneficiaries, totaling 2,053 services with total Medicare billing of $128,925. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Psychiatry
- Location Northfield, OH
- Active Since 05/01/2013
- Last Updated 07/21/2022
- Taxonomy Code 2084P0802X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1295170439
Products in Payments
- ARISTADA (Drug) $167.62
- VRAYLAR (Drug) $151.75
- PERSERIS (Drug) $136.75
- Aristada 441 mg (Drug) $104.71
- INVEGA SUSTENNA (Drug) $62.02
- ABILIFY MAINTENA (Drug) $58.45
- INGREZZA (Drug) $48.33
- AUSTEDO (Drug) $38.54
- ABILIFY MYCITE (Drug) $27.37
- ABILIFY ASIMTUFII (Drug) $19.00
- IGALMI (Drug) $18.25
- REXULTI (Drug) $17.45
- UZEDY (Drug) $17.00
- SPRAVATO (Drug) $16.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.